Upgrade to SI Premium - Free Trial

Carlisle Cos. (CSL)

367.14 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (4/23/24)

Latest Headlines

Carlisle Cos. (CSL) to Acquire MTL Holdings March 18, 2024 6:54 PM - StreetInsider Carlisle Companies to Acquire MTL Holdings, a Leader in Edge Metal and Non-Insulated Architectural Wall Systems March 18, 2024 6:47 PM - BizWire Carlisle Cos. (CSL) Files Mixed Shelf March 15, 2024 4:23 PM - StreetInsider Form S-3ASR CARLISLE COMPANIES INC March 15, 2024 4:22 PM - SEC Filing Form SC 13G/A CARLISLE COMPANIES INC Filed by: BlackRock Inc. March 7, 2024 12:30 PM - SEC Filing CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season March 6, 2024 9:01 AM - PR NewsWire Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: OSTRANDER GREGG A March 5, 2024 2:01 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: Singh Jesse G March 5, 2024 1:59 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: Ricard Corrine D. March 5, 2024 1:55 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: BOHN ROBERT G March 5, 2024 1:50 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: ADAMS ROBIN J March 5, 2024 1:47 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: Collins Jonathan R. March 5, 2024 1:42 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: Frias James D March 5, 2024 1:40 PM - SEC Filing Form PRE 14A CARLISLE COMPANIES INC For: May 01 March 1, 2024 5:25 PM - SEC Filing Travere Therapeutics (TVTX) and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy February 23, 2024 7:06 AM - StreetInsider Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy February 23, 2024 7:05 AM - Globe NewsWire CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy February 23, 2024 2:00 AM - PR NewsWire Form 4 CARLISLE COMPANIES INC For: Feb 21 Filed by: KOCH D CHRISTIAN February 22, 2024 4:22 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Feb 15 Filed by: KOCH D CHRISTIAN February 20, 2024 1:20 PM - SEC Filing Form 10-K CARLISLE COMPANIES INC For: Dec 31 February 16, 2024 2:08 PM - SEC Filing Form SC 13G/A CARLISLE COMPANIES INC Filed by: VANGUARD GROUP INC February 13, 2024 5:03 PM - SEC Filing Form 144 CARLISLE COMPANIES INC Filed by: KOCH D CHRISTIAN February 13, 2024 1:15 PM - SEC Filing Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³ February 12, 2024 10:54 PM - PR NewsWire Form 4 CARLISLE COMPANIES INC For: Feb 08 Filed by: Snyder Lori A February 12, 2024 2:45 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Feb 08 Filed by: Schwar Stephen February 12, 2024 2:05 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Feb 08 Filed by: SMITH DAVID W February 12, 2024 1:51 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Feb 08 Filed by: Selbach Scott C February 12, 2024 1:41 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Feb 08 Filed by: Berlin John E February 12, 2024 1:12 PM - SEC Filing CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human]) February 11, 2024 5:47 PM - PR NewsWire Form 144 CARLISLE COMPANIES INC Filed by: Snyder Lori A February 8, 2024 4:24 PM - SEC Filing Form 144 CARLISLE COMPANIES INC Filed by: Snyder Lori A February 8, 2024 4:10 PM - SEC Filing Form 144 CARLISLE COMPANIES INC Filed by: Schwar Stephen February 8, 2024 3:56 PM - SEC Filing Form 144 CARLISLE COMPANIES INC Filed by: Berlin John E February 8, 2024 3:11 PM - SEC Filing Form 144 CARLISLE COMPANIES INC Filed by: SMITH DAVID W February 8, 2024 2:59 PM - SEC Filing Form 144 CARLISLE COMPANIES INC Filed by: Selbach Scott C February 8, 2024 11:50 AM - SEC Filing Carlisle (CSL) PT Raised to $355 at Oppenheimer February 7, 2024 7:39 AM - StreetInsider Carlisle (CSL) PT Raised to $365 at Baird February 7, 2024 6:57 AM - StreetInsider Carlisle Cos. (CSL) Tops Q4 EPS by 68c February 6, 2024 4:14 PM - StreetInsider Form 8-K CARLISLE COMPANIES INC For: Feb 06 February 6, 2024 4:12 PM - SEC Filing Carlisle Companies Reports Fourth Quarter Results February 6, 2024 4:05 PM - BizWire Form 4 CARLISLE COMPANIES INC For: Feb 02 Filed by: SMITH DAVID W February 5, 2024 5:25 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Feb 02 Filed by: ALDRICH STEPHEN February 5, 2024 5:16 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Feb 02 Filed by: Zdimal Kevin P February 5, 2024 5:05 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Feb 02 Filed by: Snyder Lori A February 5, 2024 4:58 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Feb 02 Filed by: Selbach Scott C February 5, 2024 4:51 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Feb 02 Filed by: Schwar Stephen February 5, 2024 4:45 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Feb 02 Filed by: KOCH D CHRISTIAN February 5, 2024 4:36 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Feb 02 Filed by: Berlin John E February 5, 2024 4:27 PM - SEC Filing New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster February 5, 2024 8:30 AM - BizWire Carlisle Receives First-Ever LEED Platinum v4 Certification in North America February 1, 2024 3:15 PM - BizWire Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: OSTRANDER GREGG A January 31, 2024 2:58 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: BOHN ROBERT G January 31, 2024 2:48 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: Berlin John E January 31, 2024 2:38 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: READY FRANK J. January 31, 2024 2:29 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: Schwar Stephen January 31, 2024 2:24 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: PATEL MEHUL January 31, 2024 2:04 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: SMITH DAVID W January 31, 2024 1:55 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: ALDRICH STEPHEN January 31, 2024 1:35 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: Snyder Lori A January 31, 2024 1:17 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: Zdimal Kevin P January 31, 2024 12:56 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: Selbach Scott C January 31, 2024 12:36 PM - SEC Filing Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: KOCH D CHRISTIAN January 31, 2024 12:28 PM - SEC Filing Carlisle Cos. (CSL) Declares $0.85 Quarterly Dividend; 1.1% Yield January 30, 2024 4:06 PM - StreetInsider Carlisle Companies Declares Regular Quarterly Dividend January 30, 2024 4:05 PM - BizWire Form 8-K CARLISLE COMPANIES INC For: Jan 30 January 30, 2024 4:03 PM - SEC Filing Amphenol (APH) to Acquire CIT Business From Carlisle (CSL) for $2.025B Cash January 30, 2024 8:01 AM - StreetInsider Carlisle Companies Signs Definitive Agreement to Sell Carlisle Interconnect Technologies to Complete its Pivot to a Pure Play Building Products Company January 30, 2024 8:00 AM - BizWire Amphenol Corporation to Acquire CIT Business From Carlisle January 30, 2024 8:00 AM - BizWire Form SC 13G/A CARLISLE COMPANIES INC Filed by: BlackRock Inc. January 24, 2024 2:28 PM - SEC Filing Carlisle Companies to Announce Fourth Quarter 2023 Results on February 6, 2024 January 23, 2024 4:05 PM - BizWire Carlisle (CSL) PT Raised to $354 at Baird January 17, 2024 6:21 AM - StreetInsider Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options January 16, 2024 8:00 AM - PR NewsWire CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe January 3, 2024 8:00 AM - PR NewsWire CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)] 4- and 5-Gram Vials January 2, 2024 8:00 AM - PR NewsWire Carlisle (CSL) PT Raised to $345 at Oppenheimer January 2, 2024 7:28 AM - StreetInsider CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster December 21, 2023 8:01 AM - PR NewsWire CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster December 21, 2023 8:00 AM - BizWire Full Article List